DNA methylation is the way of allocating a chemical group to DNA. This group is typically added to key sites on the DNA, where it inhibits the proteins that attach to DNA to "read" the gene. Demethylation is a process that can be used to remove the chemical group. Typically, methylation "turns" genes "off," whereas demethylation "turns" genes "on."

Market Dynamics

Big calls for "DNA methylation" for cancer treatment

Cancer-related DNA hypo-methylation is found throughout the human genome, according to Longdom Publishing. Cancer progresses due to hyper-methylation by suppressing the tumor suppressor gene. Recent research on tissue-specific methylation has suggested that DNA hypo-methylation aids tumor transformation through a variety of pathways. Cancer-related DNA methylation absence may alter transcription. Newer research has revealed that genomic 5-hydroxymethylcytosine is an intermediate in DNA de-methylation that results in cancer-related losses. Furthermore, decreased hydroxyl-methylation and DNA methylation both play important roles in carcinogenesis. Besides that, one of the most prominent epigenetic changes observed in cancer is DNA methylation alteration. Because DNA derived from cancer cells is a stable molecule that is easily detectable in clinical specimens such as blood, sputum, urine, and stool, DNA methylation alteration in tumorigenesis has emerged as one of the promising candidate biomarkers for cancer patients' early detection, prognosis, therapeutic response prediction, and recurrence monitoring. The field of DNA methylation biomarking research is rapidly evolving, with promising results that have the potential to provide enormous benefits to cancer patients in the future.

Technological advancements bolster the growth of global DNA methylation market

According to the technique revealed in the Annals of Oncology paper, one of the mechanisms of gene expression regulation is epigenetic silencing mediated by DNA methylation. The new technology is justified by the fact that the methylation pattern found in a tumor cell differs from that of a healthy cell. The detection of DNA fragments released by tumor cells is made possible by analyzing the methylation pattern in cfDNA. Because there are many methylated regions in the DNA, this provides high sensitivity and specificity because there are many possibilities for detecting those different DNA methylated regions present in cancer. The newer technology detects genomic alterations in the DNA molecules released by tumor cells. The newer technique not only detects and monitors the presence, progression, or response of a tumor to treatment, but it also provides information about the specific mutations that a tumor has.

Market Segmentation

The global DNA methylation market is segmented based on product, application, technology, and end-user. By product, the market is segmented as enzymes, instruments and consumables, kits, reagents, and bioinformatics tools. Enzymes are further sub segmented into DNA-modifying enzymes, protein-modifying enzymes, and RNA-modifying enzymes. Further, instruments and consumables are sub segmented as next-generation sequencers, qPCR, mass spectrometers, sonicators, and others. Kits is further sub segmented as bisulfite conversion kits, ChIP-sequencing kits, RNA sequencing kits, whole genomic amplification kits, 5-hmC and 5-mC analysis kits, and others. Reagents are further sub segmented as antibodies, buffers, histones, magnetic beads, primers, and among others. By application, the market is segmented as oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases, and others. Based on application, the market is segmented as oncology, metabolic diseases, immunology, and others. Based on technology, the market is segregated as DNA methylation, histone modifications, and others. By end-user, the market is segmented as academic and research institutes, pharmaceutical and biotechnology companies, and contract research organizations (CROs)

In terms of products, reagents are expected to dominate the market during the forecast period. The most common DNA methylation enzymes are DNA-modifying enzymes, protein-modifying enzymes, and RNA-modifying enzymes. Antibodies, PCR reagents, histones, primers, electrophoresis reagents, nucleic acid reagents, and buffers are also common epigenetic reagents. “PyroMark Q24” is one of the advanced reagents that use advanced pyrosequencing chemistry to provide even better real-time sequence-based detection and quantification than previously available. In the past, DNA methylation accounted for the largest market share by technology, and this trend is expected to continue throughout the forecast period. Because DNA methylation is the covalent addition of a methyl group to the cytosine ring, it inhibits transcription. Methylation-sensitive PCR refers to sensitive bisulphite modification followed by PCR (MSP). Furthermore, by application, oncology is the largest contributor in the global DNA methylation market, with the largest share expected in the coming years. The rising prevalence of cancer worldwide, combined with an increase in cancer-related deaths, is a major contributor to segmental growth. Furthermore, the introduction of new products and the potential commercialization of products stimulate the growth of the segment, thereby contributing to the growth of the global DNA methylation market. Academic and research institutes are expected to dominate the global DNA methylation market by end-user. The Garvan Institute of Medical Research, for example, focuses on identifying DNA methylation changes associated with disease in order to improve the interpretation of diagnostic samples and guide treatment decisions.

Regional Overview

North America will take the lead in the global DNA methylation market in the coming years, with a sizable market share. The government in this region is encouraging ongoing epigenetic research activities through funding, which supports the growth of the North America regional market. But apart from that, the presence of advanced healthcare facilities and consistent advancements in diagnostic procedures stimulate regional market growth, ultimately contributing to the growth of the global DNA methylation market. One of the major factors driving the growth of the global DNA methylation market is the widespread use of technologically advanced facilities. Asia Pacific, on the other hand, is expected to grow the fastest during the forecast period due to rising disposable income, high unmet medical needs of patient group, rising awareness of early diagnosis, and availability of effective treatment options in emerging countries, particularly China and India, which stimulates the growth of the global DNA methylation market.

Competitive Landscape

The prominent players involvd in global DNA methylation market involve Illumina, Inc., Thermo Fisher Scientific, Merck Millipore, Abcam plc, Active Motif, Bio-Rad Laboratories, Inc., New England Biolabs, Agilent Technologies, Inc., QIAGEN, Zymo Research, PerkinElmer, Inc., Diagenode, and among others

Market Segmentation

Market By Product

Enzymes

• DNA-modifying Enzymes
• Protein-modifying Enzymes
• RNA-modifying Enzymes

Instruments and Consumables

• Next-generation Sequencers
• qPCR
• Mass Spectrometers
• Sonicators
• Others

Kits

• Bisulfite Conversion Kits
• ChIP-sequencing Kits
• RNA sequencing Kits
• Whole Genomic Amplification Kits
• 5-hmC and 5-mC Analysis Kits
• Others

Reagents

• Antibodies
• Buffers
• Histones
• Magnetic Beads
• Primers
• Others

Bioinformatics Tools

Market By Application

Oncology
Metabolic Diseases
Immunology
Others

Market By Technology

DNA Methylation
Histone Modifications
Others

Market By End User

Academic and Research Institutes
Pharmaceutical and Biotechnology Companies
Contract Research Organizations (CROs)

Market By Geography

North America
•    U.S.
•    Canada

Europe
•    U.K.
•    Germany
•    France
•    Spain
•    Rest of Europe

Asia-Pacific
•    China
•    Japan
•    India
•    Australia
•    South Korea
•    Rest of Asia-Pacific

Latin America
•    Brazil 
•    Mexico
•    Rest of Latin America

Middle East & Africa
•    GCC
•    South Africa
•    Rest of Middle East & Africa